Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.59 |
| ▸ | TNF | P01375 | 4/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | MUSK | O15146 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.52 |
| ▸ | PRKCB | P05771 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600328 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL1600030 | 0.84 | MAPK14 (0.57) | MAPK14EGFR | |
| SCHEMBL1599810 | 0.84 | MAPK14 (0.57) | MAPK14EGFR | |
| SCHEMBL6587109 | 0.83 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL6585227 | 0.83 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL4566793 | 0.80 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL30009966 | 0.80 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL10129913 | 0.80 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL30449051 | 0.79 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL6334316 | 0.79 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004534787-A | — | — | 2004-11-18 | — | — | JP | claimed |
| EP-1414810-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-05-06 | — | — | EP | claimed |
| US-6720321-B2 | REACTING THE ALDEHYDE WITH CARBETHOXYMETHYLENE TRIPHENYLYPHOSPHORANE TO FORM UNSATURATED ESTER, REACTING ESTER WITH DIAZOMETHANE IN PRESENCE OF PALLADIUM ACETATE TO FORM CYCLOPROPANE CABROXYLIC ESTER, HYDROLYSIS TO FORM ACID | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | claimed |
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-29 | — | — | US | claimed |
| WO-2002098869-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1414810-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6720321-B2 | REACTING THE ALDEHYDE WITH CARBETHOXYMETHYLENE TRIPHENYLYPHOSPHORANE TO FORM UNSATURATED ESTER, REACTING ESTER WITH DIAZOMETHANE IN PRESENCE OF PALLADIUM ACETATE TO FORM CYCLOPROPANE CABROXYLIC ESTER, HYDROLYSIS TO FORM ACID | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-29 | — | — | US | disclosed |
| WO-2002098869-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | MPO, NFKBIA, YBX1 | MAPK14 3283/4885MAPK13 3656/4885MAPK12 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.